Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
Tweet Send to a Friend
(Updated - June 17, 2026 6:30 AM EDT)
Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
